VRTX

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA (VRTX) has 9 SEC Form 4 filings (34 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 7, 2026.

The most active filer is EVP and CMO Bozic Carmen with 3 filings. Insiders have net sold $24.3M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Reshma Kewalramani
  • Employees:6,100
  • HQ:Boston, MA, US
  • IPO:1991-07-24

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$53.0M

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$123.4B

latest known value

Source
McKechnie DuncanFirst filing
Sale$800KJul 7SEC ↗
Tatsis OuraniaFirst filing
Sale$787KJul 7SEC ↗
Liu JoyFirst filing
Sale$416KJul 6SEC ↗
Sale$288KJun 30SEC ↗
Sale$471KJun 23SEC ↗
Bozic CarmenFirst filing
Sale$1.8MJun 17SEC ↗
Kewalramani ReshmaFirst filing
Sale$19.7MMar 3SEC ↗
LEIDEN JEFFREY MFirst filing
Sale$28.7MDec 5SEC ↗

Congress trading VRTX

See timeline →
  • DRep. Ro KhannaPurchase$1,001 - $15,0002026-04-13

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Related companies

VERTEX PHARMACEUTICALS INC / MA is in the Healthcare sector.